ORAMED PHARMACEUTICALS INC. SEC Filings

Oramed Pharmaceuticals Inc. is asking stockholders to vote at its 2026 annual meeting on six main items: electing six directors for one-year terms, ratifying Kesselman & Kesselman (a PwC member firm) as auditor for 2026, approving an amendment to the Long-Term Incentive Plan, advisory Say on Pay and Say on Frequency votes, and a potential adjournment authority.

The incentive plan amendment would increase the shares of common stock authorized for issuance under the plan by 3,000,000, bringing the total to 12,500,000. The meeting is set for September 15, 2026, in Jerusalem, with a record date of July 20, 2026, when 41,597,354 shares of common stock were outstanding and entitled to vote. A significant related-party transaction with Lifeward Ltd. transferred Oramed’s POD technology into OraTech and, at closing, yielded Oramed 1,250,363 Lifeward ordinary shares, multiple warrant positions and $9.0 million of senior secured convertible notes, with an option for an additional $9.0 million of notes upon milestones.

Oramed Pharmaceuticals COO & CBO Joshua Hexter reported an option exercise and share sale in the company’s stock. On July 2, 2026, he exercised 50,000 stock options at $3.69 per share, receiving an equal number of common shares. On July 1, 2026, he sold 137,000 common shares at a weighted average price of $4.463 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 1,073,384 common shares and 50,000 stock options that remain outstanding.

ORAMED PHARMACEUTICALS INC. Chief Financial Officer Avraham Gabay reported an open-market sale of 73,360 shares of common stock on July 1, 2026 at a weighted average price of $4.5085 per share. The transaction was executed as a planned sale under a Rule 10b5-1 trading plan adopted on March 30, 2026, indicating it was pre-arranged rather than timed discretionarily. Following this sale, Gabay directly holds 671,785 shares, showing he retains a substantial equity position in the company.

Oramed Pharmaceuticals submitted a Form 144 disclosing proposed sales of common stock. The filing lists 137,000 shares alongside a $658,970.00 value and a larger share figure 40,926,081 dated 07/01/2026. It also records 108,000 shares issued upon RSU vesting on 05/01/2023 and 50,000 shares acquired on 07/01/2026 upon option exercise.

Oramed Pharmaceuticals Inc. submitted a Form 144 concerning Common Stock. The filing lists 93,360 shares tied to shares issued upon vesting of RSUs on 06/18/2026, notes Nasdaq as the market, and shows an associated date of 07/01/2026.

The filing text states the shares were issued with “No consideration, shares issued upon vesting of RSUs.” The notice appears procedural and lists header values including 449,061.60 and 40,926,081 in the securities section.

Oramed Pharmaceuticals Inc. updated its corporate bylaws and restructured payment timing on large notes owed by Scilex Holding Company. The board approved Fifth Amended and Restated Bylaws, which adjust how record dates and written stockholder consents are set and delivered.

Separately, Oramed agreed to extend repayment of Scilex’s Obligations under a Senior Secured Promissory Note and a Senior Secured Convertible Note, totaling about $29.5 million on the Tranche A Note and about $6.7 million on the Tranche B Note. Scilex will pay $0.5 million received on June 25, 2026, $5 million by July 31, 2026, and the remaining balance by September 30, 2026, with a mechanism that can recharacterize $1.5 million as an extension fee if full repayment is not made, and a provision to settle remaining amounts in registered common stock of Scilex or an affiliate.

Oramed Pharmaceuticals Inc. reports amended Schedule 13G/A ownership by BML Investment Partners, L.P. The filing states BML Investment Partners, L.P. beneficially owns 1,026,269 shares of Common Stock, representing 2.5% of the class. The filing attributes shared voting and dispositive power of 866,269 shares and sole power over 160,000 shares.

The filing explains that BML Capital Management, LLC is the general partner and that Braden M. Leonard is the managing member and deemed indirect owner; the reporting persons disclaim being a statutory group under Rule 13d-5(b)(1).

Oramed Pharmaceuticals reported net income of $38.3M for the three months ended March 31, 2026, compared with a net loss of $7.6M a year earlier. Basic EPS was $0.94.

Operating loss narrowed to $3.7M as research and development and general and administrative expenses declined. The swing to profitability was driven mainly by $44.8M of net financial income, including large fair value gains on investments such as Alpha Tau and Scilex, plus $8.3M of other income from a POD technology IP sale and recognizing $2.0M under the Medicox license.

Cash and cash equivalents fell to $13.2M from $45.9M at year-end 2025, while total assets increased to $268.8M as investment balances grew. The company completed the Lifeward transaction, transferring its POD technology into OraTech and receiving Lifeward shares, warrants and a convertible note, and it expanded its portfolio of structured investments and real estate–backed loans.

Oramed Pharmaceuticals Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The company states it requires additional time to complete and finalize the financial statements and currently anticipates filing on or before the fifth calendar day following the prescribed due date. The notification is signed by Nadav Kidron, President and Chief Executive Officer, on May 15, 2026.